Global Recombinant Glucocerebrosidase Market Research Report 2024

Publication ID:

PB510243597

Publication Date:

October 15, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Recombinant glucocerebrosidase is an engineered enzyme produced using recombinant DNA technology, aimed at treating Gaucher's disease, a genetic disorder caused by the deficiency of the natural enzyme. This therapy helps break down glucocerebroside, a fatty substance that accumulates in cells, alleviating symptoms and improving patient quality of life.
The global Recombinant Glucocerebrosidase market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Recombinant Glucocerebrosidase is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Recombinant Glucocerebrosidase is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Recombinant Glucocerebrosidase include Pfizer, Takeda Pharmaceuticals, Sanofi, ISU Abxis, Protalix Biotherapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Glucocerebrosidase, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Glucocerebrosidase.
The Recombinant Glucocerebrosidase market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Recombinant Glucocerebrosidase market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Glucocerebrosidase manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Pfizer
Takeda Pharmaceuticals
Sanofi
ISU Abxis
Protalix Biotherapeutics
Segment by Type
Imiglucerase
Velaglucerase Alfa
Taliglucerase Alfa
Segment by Application
Hospital and Clinic
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Glucocerebrosidase manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Glucocerebrosidase in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Recombinant Glucocerebrosidase Market Overview
1.1 Product Definition
1.2 Recombinant Glucocerebrosidase by Type
1.2.1 Global Recombinant Glucocerebrosidase Market Value Comparison by Type (2024-2030)
1.2.2 Imiglucerase
1.2.3 Velaglucerase Alfa
1.2.4 Taliglucerase Alfa
1.3 Recombinant Glucocerebrosidase by Application
1.3.1 Global Recombinant Glucocerebrosidase Market Value by Application (2024-2030)
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Recombinant Glucocerebrosidase Market Size Estimates and Forecasts
1.4.1 Global Recombinant Glucocerebrosidase Revenue 2019-2030
1.4.2 Global Recombinant Glucocerebrosidase Sales 2019-2030
1.4.3 Global Recombinant Glucocerebrosidase Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant Glucocerebrosidase Market Competition by Manufacturers
2.1 Global Recombinant Glucocerebrosidase Sales Market Share by Manufacturers (2019-2024)
2.2 Global Recombinant Glucocerebrosidase Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Recombinant Glucocerebrosidase Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Recombinant Glucocerebrosidase, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Glucocerebrosidase, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Glucocerebrosidase, Product Type & Application
2.7 Global Key Manufacturers of Recombinant Glucocerebrosidase, Date of Enter into This Industry
2.8 Global Recombinant Glucocerebrosidase Market Competitive Situation and Trends
2.8.1 Global Recombinant Glucocerebrosidase Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Recombinant Glucocerebrosidase Players Market Share by Revenue
2.8.3 Global Recombinant Glucocerebrosidase Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Recombinant Glucocerebrosidase Market Scenario by Region
3.1 Global Recombinant Glucocerebrosidase Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant Glucocerebrosidase Sales by Region: 2019-2030
3.2.1 Global Recombinant Glucocerebrosidase Sales by Region: 2019-2024
3.2.2 Global Recombinant Glucocerebrosidase Sales by Region: 2025-2030
3.3 Global Recombinant Glucocerebrosidase Revenue by Region: 2019-2030
3.3.1 Global Recombinant Glucocerebrosidase Revenue by Region: 2019-2024
3.3.2 Global Recombinant Glucocerebrosidase Revenue by Region: 2025-2030
3.4 North America Recombinant Glucocerebrosidase Market Facts & Figures by Country
3.4.1 North America Recombinant Glucocerebrosidase Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant Glucocerebrosidase Sales by Country (2019-2030)
3.4.3 North America Recombinant Glucocerebrosidase Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant Glucocerebrosidase Market Facts & Figures by Country
3.5.1 Europe Recombinant Glucocerebrosidase Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant Glucocerebrosidase Sales by Country (2019-2030)
3.5.3 Europe Recombinant Glucocerebrosidase Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Glucocerebrosidase Market Facts & Figures by Region
3.6.1 Asia Pacific Recombinant Glucocerebrosidase Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant Glucocerebrosidase Sales by Region (2019-2030)
3.6.3 Asia Pacific Recombinant Glucocerebrosidase Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Recombinant Glucocerebrosidase Market Facts & Figures by Country
3.7.1 Latin America Recombinant Glucocerebrosidase Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant Glucocerebrosidase Sales by Country (2019-2030)
3.7.3 Latin America Recombinant Glucocerebrosidase Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Recombinant Glucocerebrosidase Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Glucocerebrosidase Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant Glucocerebrosidase Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant Glucocerebrosidase Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Glucocerebrosidase Sales by Type (2019-2030)
4.1.1 Global Recombinant Glucocerebrosidase Sales by Type (2019-2024)
4.1.2 Global Recombinant Glucocerebrosidase Sales by Type (2025-2030)
4.1.3 Global Recombinant Glucocerebrosidase Sales Market Share by Type (2019-2030)
4.2 Global Recombinant Glucocerebrosidase Revenue by Type (2019-2030)
4.2.1 Global Recombinant Glucocerebrosidase Revenue by Type (2019-2024)
4.2.2 Global Recombinant Glucocerebrosidase Revenue by Type (2025-2030)
4.2.3 Global Recombinant Glucocerebrosidase Revenue Market Share by Type (2019-2030)
4.3 Global Recombinant Glucocerebrosidase Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant Glucocerebrosidase Sales by Application (2019-2030)
5.1.1 Global Recombinant Glucocerebrosidase Sales by Application (2019-2024)
5.1.2 Global Recombinant Glucocerebrosidase Sales by Application (2025-2030)
5.1.3 Global Recombinant Glucocerebrosidase Sales Market Share by Application (2019-2030)
5.2 Global Recombinant Glucocerebrosidase Revenue by Application (2019-2030)
5.2.1 Global Recombinant Glucocerebrosidase Revenue by Application (2019-2024)
5.2.2 Global Recombinant Glucocerebrosidase Revenue by Application (2025-2030)
5.2.3 Global Recombinant Glucocerebrosidase Revenue Market Share by Application (2019-2030)
5.3 Global Recombinant Glucocerebrosidase Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Recombinant Glucocerebrosidase Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Recombinant Glucocerebrosidase Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Takeda Pharmaceuticals
6.2.1 Takeda Pharmaceuticals Company Information
6.2.2 Takeda Pharmaceuticals Description and Business Overview
6.2.3 Takeda Pharmaceuticals Recombinant Glucocerebrosidase Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Takeda Pharmaceuticals Recombinant Glucocerebrosidase Product Portfolio
6.2.5 Takeda Pharmaceuticals Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Recombinant Glucocerebrosidase Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Recombinant Glucocerebrosidase Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 ISU Abxis
6.4.1 ISU Abxis Company Information
6.4.2 ISU Abxis Description and Business Overview
6.4.3 ISU Abxis Recombinant Glucocerebrosidase Sales, Revenue and Gross Margin (2019-2024)
6.4.4 ISU Abxis Recombinant Glucocerebrosidase Product Portfolio
6.4.5 ISU Abxis Recent Developments/Updates
6.5 Protalix Biotherapeutics
6.5.1 Protalix Biotherapeutics Company Information
6.5.2 Protalix Biotherapeutics Description and Business Overview
6.5.3 Protalix Biotherapeutics Recombinant Glucocerebrosidase Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Protalix Biotherapeutics Recombinant Glucocerebrosidase Product Portfolio
6.5.5 Protalix Biotherapeutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Glucocerebrosidase Industry Chain Analysis
7.2 Recombinant Glucocerebrosidase Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Glucocerebrosidase Production Mode & Process
7.4 Recombinant Glucocerebrosidase Sales and Marketing
7.4.1 Recombinant Glucocerebrosidase Sales Channels
7.4.2 Recombinant Glucocerebrosidase Distributors
7.5 Recombinant Glucocerebrosidase Customers
8 Recombinant Glucocerebrosidase Market Dynamics
8.1 Recombinant Glucocerebrosidase Industry Trends
8.2 Recombinant Glucocerebrosidase Market Drivers
8.3 Recombinant Glucocerebrosidase Market Challenges
8.4 Recombinant Glucocerebrosidase Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Pfizer
Takeda Pharmaceuticals
Sanofi
ISU Abxis
Protalix Biotherapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂